AR017780A1 - Conjugado del factor de liberacion de hormona de crecimiento-polietilenenglicol (hgrf-peg) y metodo para la preparacion en sitio-especifico del mismo. - Google Patents

Conjugado del factor de liberacion de hormona de crecimiento-polietilenenglicol (hgrf-peg) y metodo para la preparacion en sitio-especifico del mismo.

Info

Publication number
AR017780A1
AR017780A1 ARP980106098A ARP980106098A AR017780A1 AR 017780 A1 AR017780 A1 AR 017780A1 AR P980106098 A ARP980106098 A AR P980106098A AR P980106098 A ARP980106098 A AR P980106098A AR 017780 A1 AR017780 A1 AR 017780A1
Authority
AR
Argentina
Prior art keywords
hgrf
peg
preparation
conjugate
growth
Prior art date
Application number
ARP980106098A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR017780A1 publication Critical patent/AR017780A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

Se trata de conjungados hGRF-PEG que tienen al menos una unidad PEG (por mol de hGRF) covalentemente ligada a Lys12 y/o Lys21 y/o Nalfa. También se proponela preparacion de dichos conjugados mediante la reaccion de conjugacion entre el péptido hGRFy el PEG activado, conducida en una solucion; el conjugado hGRF-PEG deseado puede ser purificado por cromatografía. Los conjugados preparados mediante éste método así como también su uso en la preparacion de medicamentospara el tratamiento,prevencion o diagnosis de las deficiencias de la hormona de crecimiento se constituye también son objetos reivindicados expresamente.
ARP980106098A 1997-12-03 1998-12-02 Conjugado del factor de liberacion de hormona de crecimiento-polietilenenglicol (hgrf-peg) y metodo para la preparacion en sitio-especifico del mismo. AR017780A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121264A EP0922446A1 (en) 1997-12-03 1997-12-03 Solution-phase site-specific preparation of GRF-PEG conjugates

Publications (1)

Publication Number Publication Date
AR017780A1 true AR017780A1 (es) 2001-10-24

Family

ID=8227732

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106098A AR017780A1 (es) 1997-12-03 1998-12-02 Conjugado del factor de liberacion de hormona de crecimiento-polietilenenglicol (hgrf-peg) y metodo para la preparacion en sitio-especifico del mismo.

Country Status (30)

Country Link
US (3) US6528485B1 (es)
EP (2) EP0922446A1 (es)
JP (2) JP2001524505A (es)
KR (1) KR100561768B1 (es)
CN (1) CN1149967C (es)
AR (1) AR017780A1 (es)
AT (1) ATE236607T1 (es)
AU (1) AU755285B2 (es)
BG (1) BG64815B1 (es)
BR (1) BR9815159A (es)
CA (1) CA2312004C (es)
DE (1) DE69813291T2 (es)
DK (1) DK1037587T3 (es)
EA (1) EA004269B1 (es)
EE (1) EE200000319A (es)
ES (1) ES2194376T3 (es)
HK (1) HK1034203A1 (es)
HU (1) HUP0100507A3 (es)
IL (2) IL136551A0 (es)
NO (1) NO327238B1 (es)
NZ (1) NZ504570A (es)
PL (1) PL192082B1 (es)
PT (1) PT1037587E (es)
SI (1) SI1037587T1 (es)
SK (1) SK8242000A3 (es)
TR (1) TR200001615T2 (es)
TW (1) TWI254641B (es)
UA (1) UA73716C2 (es)
WO (1) WO1999027897A1 (es)
ZA (1) ZA9811068B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
CA2422707A1 (en) * 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
ATE371680T1 (de) * 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
JP4339797B2 (ja) * 2003-01-18 2009-10-07 ペスフェア カンパニー リミテッド 非標的部位のアミンが保護されたペプチド、その製造方法、及びこれを利用したｐｅｇが特異的に接合されたペプチドの製造方法
CA2532250A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
WO2005010163A2 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
CN1925843A (zh) * 2003-12-02 2007-03-07 细胞免疫科学公司 生产单克隆抗体的方法和组合物
WO2005072893A1 (en) * 2004-01-28 2005-08-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
LT1824988T (lt) 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
EP1907067B2 (en) * 2005-07-26 2017-06-28 Solvay USA Inc. Polymers with pendant poly(alkyleneoxy) substituent groups and their use in personal care applications
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2444499A3 (en) 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
ES2529234T3 (es) * 2006-08-04 2015-02-18 Prolong Pharmaceuticals, LLC Eritropoyetina modificada
US20080083154A1 (en) * 2006-10-05 2008-04-10 Timothy M Gregory Bait retention fish hook
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
EP2200932A4 (en) * 2007-09-21 2014-09-10 Cytimmune Sciences Inc NANOTHERAPEUTIC COLLOIDAL METAL COMPOSITIONS AND METHODS
CA2706700A1 (en) * 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
CN102272151B (zh) * 2008-11-04 2014-08-20 詹森药业有限公司 Crhr2肽激动剂及其用途
CA2755395C (en) * 2009-03-20 2015-02-24 Hanmi Holdings Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
WO2010121351A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
WO2010121352A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
CA2780163A1 (en) * 2009-11-04 2011-05-12 Janssen Pharmaceutica Nv Method for treating heart failure with stresscopin-like peptides
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
MX2013012259A (es) 2011-04-21 2013-11-22 Theratechnologies Inc Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
US10519239B2 (en) 2015-05-28 2019-12-31 Institut National De La Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
JP7134093B2 (ja) 2016-04-19 2022-09-09 グリフォン・ファーマシューティカルズ・アンテルナシオナル・エスアー ペグ化バイオアクティブペプチド及びその使用
CN110317826B (zh) * 2019-05-22 2020-11-10 中国农业大学 调控PvGRF9含量或活性的物质在调控植物茎生长发育中的应用
WO2021133407A1 (en) 2019-12-27 2021-07-01 Compagnie Generale Des Etablissements Michelin Rubber mix with high specific surface area and high structure acetylene carbon black
WO2022165039A1 (en) 2021-01-28 2022-08-04 Talem Therapeutics Llc Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
DK0400472T3 (da) * 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
AU656144B2 (en) * 1990-06-29 1995-01-27 F. Hoffmann-La Roche Ag Histidine substituted growth hormone releasing factor analogs
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
CA2084061A1 (en) * 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
EP0518295A3 (en) * 1991-06-14 1993-09-01 Millipore Corporation Allyl side chain protection in peptide synthesis
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1997017367A1 (en) * 1995-11-03 1997-05-15 Theratechnologies Inc. Method of grf peptides synthesis

Also Published As

Publication number Publication date
PL192082B1 (pl) 2006-08-31
KR100561768B1 (ko) 2006-03-16
ES2194376T3 (es) 2003-11-16
CA2312004A1 (en) 1999-06-10
HK1034203A1 (en) 2001-10-19
WO1999027897A1 (en) 1999-06-10
JP5431874B2 (ja) 2014-03-05
PT1037587E (pt) 2003-08-29
TWI254641B (en) 2006-05-11
CN1280483A (zh) 2001-01-17
NZ504570A (en) 2003-10-31
US6528485B1 (en) 2003-03-04
BR9815159A (pt) 2000-10-10
KR20010032494A (ko) 2001-04-25
ZA9811068B (en) 1999-06-28
TR200001615T2 (tr) 2000-12-21
NO20002664L (no) 2000-07-13
PL341139A1 (en) 2001-03-26
EA004269B1 (ru) 2004-02-26
BG64815B1 (bg) 2006-05-31
UA73716C2 (en) 2005-09-15
US20050159353A1 (en) 2005-07-21
NO327238B1 (no) 2009-05-18
WO1999027897A9 (en) 1999-09-30
DE69813291T2 (de) 2003-11-13
BG104484A (en) 2000-12-29
EE200000319A (et) 2001-08-15
AU1563399A (en) 1999-06-16
HUP0100507A2 (hu) 2001-08-28
HUP0100507A3 (en) 2001-11-28
IL136551A (en) 2008-12-29
US6869932B2 (en) 2005-03-22
JP2001524505A (ja) 2001-12-04
US20040029794A1 (en) 2004-02-12
EP0922446A1 (en) 1999-06-16
NO20002664D0 (no) 2000-05-24
ATE236607T1 (de) 2003-04-15
IL136551A0 (en) 2001-06-14
SI1037587T1 (en) 2003-08-31
SK8242000A3 (en) 2001-01-18
CA2312004C (en) 2009-05-19
EP1037587B1 (en) 2003-04-09
DE69813291D1 (de) 2003-05-15
EP1037587A1 (en) 2000-09-27
AU755285B2 (en) 2002-12-05
DK1037587T3 (da) 2003-07-28
CN1149967C (zh) 2004-05-19
EA200000601A1 (ru) 2000-12-25
US7317002B2 (en) 2008-01-08
JP2010024245A (ja) 2010-02-04

Similar Documents

Publication Publication Date Title
AR017780A1 (es) Conjugado del factor de liberacion de hormona de crecimiento-polietilenenglicol (hgrf-peg) y metodo para la preparacion en sitio-especifico del mismo.
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
EP0804595A4 (es)
AR008378A1 (es) Conjudados de interferon
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
MX9700552A (es) Conjugados de vitamina b12 y proteinas.
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
PT779805E (pt) Libertacao sustentada de peptidos de composicoes farmaceuticas
ATE332918T1 (de) Neoglycoproteine
ATE344801T1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
ES2173943T3 (es) Sulfonas activas de polietilenglicol solubles en agua.
UA66857C2 (uk) КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
TR200001977T2 (tr) Lipofilik glukokortikosteroit içeren miseller ihtiva eden bileşimler
DE60024491D1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
BR9506847A (pt) Composto composição farmacêutica uso de um composto processo para o tratamento da dor
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
EA200400592A1 (ru) КОНЪЮГАТЫ ПЕПТИДА ТИМОЗИН α1 И ПОЛИМЕРА
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
ATE110280T1 (de) Zum wirkort hingeführte und dort angereicherte aktivsubstanzen.
ES2220256T1 (es) Albumina humana terapeutica con baja actividad para la fijacion de aluminio.
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
ES2163725T3 (es) Derivados 7,12-dioxa-benzo-(a)-antracenicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2172949T3 (es) Composiciones destinadas para la administracion transcutanea y cutanea de agentes biologicamente activos.

Legal Events

Date Code Title Description
FG Grant, registration